Confluence Wealth Services Inc. lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 251.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,162 shares of the biopharmaceutical company's stock after purchasing an additional 7,986 shares during the quarter. Confluence Wealth Services Inc.'s holdings in Gilead Sciences were worth $1,410,000 as of its most recent SEC filing.

• 3 Blue-Chip Stocks Built for a Rotating Market

A number of other hedge funds have also added to or reduced their stakes in GILD. Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences during the 4th quarter worth about $25,000. Vermillion & White Wealth Management Group LLC raised its holdings in Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 85 shares in the last quarter. Quattro Advisors LLC acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $26,000. Wealth Preservation Advisors LLC grew its stake in Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 81 shares in the last quarter. Finally, Ares Financial Consulting LLC acquired a new position in shares of Gilead Sciences during the 4th quarter worth approximately $28,000. Institutional investors own 83.67% of the company's stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Strong Q2 operating trends: Analysts highlighted continued year-over-year sales growth led by Biktarvy and the HIV prevention franchise. Quarterly PrEP sales reportedly doubled to more than $1 billion, while Trodelvy and Livdelzi contributed to growth in oncology and liver disease. 5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
• Positive Sentiment: AI oncology collaboration: Gilead partnered with Nucleai to apply AI-powered tissue analytics to its antibody-drug conjugate programs. The technology could accelerate biomarker discovery and support more precise development of Gilead’s oncology pipeline. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Partnership and pipeline optionality: Gilead’s collaboration with Merck is being viewed as a potential growth engine, with recent clinical and regulatory progress supporting the strategic value of combining the companies’ capabilities. Could Merck and Gilead’s Partnership Create the Next Big Pharma Growth Engine
• Positive Sentiment: Assembly Biosciences collaboration: Assembly expanded development of ABI-6250 and reported a $115 million financing, while its cash runway includes a Gilead collaboration extension. The update supports continued advancement of programs associated with Gilead’s partnership. Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
• Positive Sentiment: Analyst and options signals: Analysts cited a consensus price target of $158.04, above the recent trading level, while unusually high call-option activity reflected increased bullish interest. Investors Purchase High Volume of Gilead Sciences Call Options Gilead Receives Consensus Target Price
• Neutral Sentiment: Valuation remains a debate: Despite a substantial multiyear return, commentary suggests Gilead still appears reasonably valued based on sales, leaving room for further gains if growth initiatives continue. Gilead Stock Still Looks Cheap on Sales
• Negative Sentiment: Mixed earnings-estimate revisions: Erste Group Bank modestly reduced its FY2026 EPS forecast to $(0.75) from $(0.74), below the broader consensus estimate of $(0.53), signaling some caution around near-term profitability. Erste Group Bank Estimates Gilead Sciences FY2027 Earnings

Gilead Sciences Stock Performance

• These 3 Cash Flow Machines Provide Stability in Uncertain Markets

NASDAQ GILD opened at $138.14 on Friday. The firm has a 50-day moving average price of $129.93 and a two-hundred day moving average price of $136.44. Gilead Sciences, Inc. has a 12-month low of $108.46 and a 12-month high of $157.29. The company has a market capitalization of $171.29 billion, a P/E ratio of -51.74 and a beta of 0.32. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping the consensus estimate of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to analysts' expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business's revenue for the quarter was up 10.6% on a year-over-year basis. During the same period last year, the firm earned $2.01 earnings per share. Analysts anticipate that Gilead Sciences, Inc. will post -0.53 earnings per share for the current year.

Gilead Sciences Dividend Announcement

• 3 Cash-Flow Machines Investors May Want Heading Into 2026

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be issued a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.4%. Gilead Sciences's payout ratio is currently -122.85%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the company's stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the sale, the chief financial officer owned 171,646 shares of the company's stock, valued at $21,524,408.40. This represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the completion of the transaction, the insider directly owned 124,234 shares in the company, valued at approximately $15,395,077.28. This represents a 2.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 51,000 shares of company stock worth $6,568,860. 0.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Barclays cut their price objective on Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating for the company in a report on Wednesday, July 29th. Leerink Partners lowered shares of Gilead Sciences from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $146.00 to $127.00 in a research note on Tuesday, July 21st. HSBC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and raised their target price for the company from $133.00 to $155.00 in a research note on Monday, July 6th. Maxim Group upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 price objective on the stock in a research note on Wednesday, May 20th. Finally, Wall Street Zen downgraded Gilead Sciences from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Twenty-four equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $158.04.

Read Our Latest Stock Report on Gilead Sciences

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Featured Stories

• Five stocks we like better than Gilead Sciences
• Asian Market Circuit Breakers Hit Stocks, Not AI Demand
• Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
• Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
• Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Gilead Sciences Right Now?

Before you consider Gilead Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.

While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here